Targeted therapy for advanced colorectal cancer - more is not always better

New England Journal of Medicine

Volumn 360, Issue 6, 2009, Pages 623-625

  Mayer, Robert J ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADVANCED CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; EDITORIAL; HUMAN; INFECTION; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; SURVIVAL TIME; COLORECTAL TUMOR; DRUG ANTAGONISM; IMMUNOLOGY; NOTE; TREATMENT FAILURE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; FLUOROURACIL; HUMANS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT FAILURE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 59749089432     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0809343     Document Type: Editorial

References (10)

1. Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology 2008;134:1296-310.
2. DeVita VT, Schein PS. The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med 1973;288:998-1006.
3. Van Cutsem E, Nowacki M, Lang I, et al. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first line treatment of patients with metastatic colorectal cancer. J Clin Oncol 2007;25:164s. abstract.
4. Karapetis CS, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008;359:1757-66.
5. Van Cutsem E, Lang I, D'Haens G, et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab. J Clin Oncol 2008;26:1006s. abstract.
6. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-34.
7. Shaheen RM, Ahmed SA, Liu W, et al. Inhibited growth of colon cancer carcinomatosis by antibodies to vascular endothelial and epidermal growth factor receptors. Br J Cancer 2001; 85:584-9.
8. Saltz LB, Lenz HJ, Kindler HL, et al. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study. J Clin Oncol 2007;25: 4557-61.
9. Tol J, Koopman M, Cats A, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009;360:563-72.
10. Hecht JR, Mitchell E, Chidiac T, et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol (in press).